🇺🇸 FDA
Patent

US 10308687

Cell-penetrating compstatin analogs and uses thereof

granted A61KA61K38/00A61K47/645

Quick answer

US patent 10308687 (Cell-penetrating compstatin analogs and uses thereof) held by Apellis Pharmaceuticals, Inc. expires Mon May 30 2039 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.

Key facts

Applicant
Apellis Pharmaceuticals, Inc.
Grant date
Tue Jun 04 2019 00:00:00 GMT+0000 (Coordinated Universal Time)
Expiration
Mon May 30 2039 00:00:00 GMT+0000 (Coordinated Universal Time)
Claims
13
CPC classes
A61K, A61K38/00, A61K47/645